CN103619825B - 可用于治疗神经退化性疾病的1,2,4-噻二唑-5-基哌嗪衍生物 - Google Patents
可用于治疗神经退化性疾病的1,2,4-噻二唑-5-基哌嗪衍生物 Download PDFInfo
- Publication number
- CN103619825B CN103619825B CN201280030881.0A CN201280030881A CN103619825B CN 103619825 B CN103619825 B CN 103619825B CN 201280030881 A CN201280030881 A CN 201280030881A CN 103619825 B CN103619825 B CN 103619825B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- thiadiazol
- piperazine
- ethyl
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*1c(*NC)*c(*2CC*(*)CC2)[n]1 Chemical compound C*1c(*NC)*c(*2CC*(*)CC2)[n]1 0.000 description 7
- IMGUHIWIBSSTMC-UHFFFAOYSA-N COc1cc(CCC(CC2)CCN2c2nc(-c(cc3F)ccc3F)n[s]2)ccn1 Chemical compound COc1cc(CCC(CC2)CCN2c2nc(-c(cc3F)ccc3F)n[s]2)ccn1 IMGUHIWIBSSTMC-UHFFFAOYSA-N 0.000 description 1
- HQGQUNSFWGWBFG-UHFFFAOYSA-N COc1ccc(CCN(CC2)CCN2c2nc(-c(cc3)cc(F)c3F)n[s]2)cc1 Chemical compound COc1ccc(CCN(CC2)CCN2c2nc(-c(cc3)cc(F)c3F)n[s]2)cc1 HQGQUNSFWGWBFG-UHFFFAOYSA-N 0.000 description 1
- SXCLTFRQEZSXFQ-UHFFFAOYSA-N COc1ccc(CCN(CC2)CCN2c2nc(-c(cc3)ccc3Cl)n[s]2)cn1 Chemical compound COc1ccc(CCN(CC2)CCN2c2nc(-c(cc3)ccc3Cl)n[s]2)cn1 SXCLTFRQEZSXFQ-UHFFFAOYSA-N 0.000 description 1
- ZBRVNSDRHKCHPE-UHFFFAOYSA-N COc1cccc(CCN(CC2)CCN2c2nc(-c(ccc(F)c3)c3OC)n[s]2)c1 Chemical compound COc1cccc(CCN(CC2)CCN2c2nc(-c(ccc(F)c3)c3OC)n[s]2)c1 ZBRVNSDRHKCHPE-UHFFFAOYSA-N 0.000 description 1
- WZXLJQFOOKUNSK-UHFFFAOYSA-N Cc(cc1)ccc1-c1n[s]c(N2CCN(Cc3ccc4OCOc4c3)CC2)n1 Chemical compound Cc(cc1)ccc1-c1n[s]c(N2CCN(Cc3ccc4OCOc4c3)CC2)n1 WZXLJQFOOKUNSK-UHFFFAOYSA-N 0.000 description 1
- JEXCGMAHECZNFB-UHFFFAOYSA-N FC(c1ccc(CC[I]2CCC(CC3=[I]C(C(C4)C=NC=C4Cl)=CS3)=CCC2)cc1)(F)F Chemical compound FC(c1ccc(CC[I]2CCC(CC3=[I]C(C(C4)C=NC=C4Cl)=CS3)=CCC2)cc1)(F)F JEXCGMAHECZNFB-UHFFFAOYSA-N 0.000 description 1
- KKZCJEJXBUIJRQ-UHFFFAOYSA-N N#Cc(cc1)ccc1-c1n[s]c(N2CCN(CCc(cc3)ccc3Cl)CC2)n1 Chemical compound N#Cc(cc1)ccc1-c1n[s]c(N2CCN(CCc(cc3)ccc3Cl)CC2)n1 KKZCJEJXBUIJRQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11172324.3 | 2011-07-01 | ||
| EP11172324 | 2011-07-01 | ||
| PCT/EP2012/062778 WO2013004642A1 (en) | 2011-07-01 | 2012-06-29 | 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103619825A CN103619825A (zh) | 2014-03-05 |
| CN103619825B true CN103619825B (zh) | 2015-10-14 |
Family
ID=46545347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280030881.0A Active CN103619825B (zh) | 2011-07-01 | 2012-06-29 | 可用于治疗神经退化性疾病的1,2,4-噻二唑-5-基哌嗪衍生物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9023852B2 (https=) |
| EP (1) | EP2726470B1 (https=) |
| JP (1) | JP5972367B2 (https=) |
| CN (1) | CN103619825B (https=) |
| AU (1) | AU2012280420B2 (https=) |
| CA (1) | CA2837247C (https=) |
| ES (1) | ES2540956T3 (https=) |
| PL (1) | PL2726470T3 (https=) |
| WO (1) | WO2013004642A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9187440B2 (en) * | 2011-08-17 | 2015-11-17 | Remynd Nv | Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease |
| WO2015140130A1 (en) * | 2014-03-17 | 2015-09-24 | Remynd Nv | Oxadiazole compounds |
| SG11201811023UA (en) | 2016-06-23 | 2019-01-30 | St Jude Childrens Res Hospital | Small molecule modulators of pantothenate kinases |
| JP2019533022A (ja) * | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス，インコーポレーテッド | 化合物及びその使用 |
| EP3566055B1 (en) | 2017-01-06 | 2025-03-12 | Janssen Pharmaceutica NV | Scd inhibitor for the treatment of neurological disorders |
| CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| WO2019133635A1 (en) | 2017-12-27 | 2019-07-04 | St. Jude Children's Research Hospital | Small molecule modulators of pantothenate kinases |
| JP7527967B2 (ja) | 2017-12-27 | 2024-08-05 | セント ジュード チルドレンズ リサーチ ホスピタル，インコーポレイティド | Ｃａｓｔｏｒに関連する障害を治療する方法 |
| WO2019183587A1 (en) | 2018-03-23 | 2019-09-26 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| WO2020154571A1 (en) | 2019-01-24 | 2020-07-30 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| WO2025104092A1 (en) | 2023-11-13 | 2025-05-22 | Remynd N.V. | Modulators of septin 6 for use in the prevention and/or treatment of neurodegenerative disorders |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1348449A (zh) * | 1999-04-26 | 2002-05-08 | 神经研究公司 | 杂芳基二氮杂环烷烃及其制备方法和应用 |
| CN1349520A (zh) * | 1999-03-03 | 2002-05-15 | 美国家用产品公司 | 用作5－羟色胺能药物的新型二唑衍生物 |
| CN101378757A (zh) * | 2006-02-07 | 2009-03-04 | 瑞敏德股份有限公司 | 治疗神经变性疾病的噻二唑衍生物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004032567A1 (de) * | 2004-07-05 | 2006-03-02 | Grünenthal GmbH | Substituierte 1-Propiolyl-piperazine |
| US7541359B2 (en) * | 2005-06-30 | 2009-06-02 | Janssen Pharmaceutica N.V. | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase |
| WO2007092435A2 (en) * | 2006-02-07 | 2007-08-16 | Wyeth | 11-beta hsd1 inhibitors |
-
2012
- 2012-06-29 AU AU2012280420A patent/AU2012280420B2/en not_active Ceased
- 2012-06-29 ES ES12737238.1T patent/ES2540956T3/es active Active
- 2012-06-29 CA CA2837247A patent/CA2837247C/en active Active
- 2012-06-29 WO PCT/EP2012/062778 patent/WO2013004642A1/en not_active Ceased
- 2012-06-29 PL PL12737238T patent/PL2726470T3/pl unknown
- 2012-06-29 JP JP2014517749A patent/JP5972367B2/ja not_active Expired - Fee Related
- 2012-06-29 CN CN201280030881.0A patent/CN103619825B/zh active Active
- 2012-06-29 EP EP20120737238 patent/EP2726470B1/en active Active
- 2012-06-29 US US14/127,779 patent/US9023852B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1349520A (zh) * | 1999-03-03 | 2002-05-15 | 美国家用产品公司 | 用作5－羟色胺能药物的新型二唑衍生物 |
| CN1348449A (zh) * | 1999-04-26 | 2002-05-08 | 神经研究公司 | 杂芳基二氮杂环烷烃及其制备方法和应用 |
| CN101378757A (zh) * | 2006-02-07 | 2009-03-04 | 瑞敏德股份有限公司 | 治疗神经变性疾病的噻二唑衍生物 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2726470A1 (en) | 2014-05-07 |
| WO2013004642A1 (en) | 2013-01-10 |
| JP5972367B2 (ja) | 2016-08-17 |
| ES2540956T3 (es) | 2015-07-15 |
| AU2012280420A1 (en) | 2013-12-12 |
| JP2014518240A (ja) | 2014-07-28 |
| CA2837247C (en) | 2020-03-31 |
| AU2012280420B2 (en) | 2017-01-05 |
| US9023852B2 (en) | 2015-05-05 |
| CN103619825A (zh) | 2014-03-05 |
| CA2837247A1 (en) | 2013-01-10 |
| US20140128404A1 (en) | 2014-05-08 |
| EP2726470B1 (en) | 2015-04-29 |
| PL2726470T3 (pl) | 2015-09-30 |
| HK1192726A1 (en) | 2014-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103619825B (zh) | 可用于治疗神经退化性疾病的1,2,4-噻二唑-5-基哌嗪衍生物 | |
| EP1678171B1 (en) | 2-amino-4-thiazolone-pyrimidine derivatives as protein kinase inhibitors | |
| JP5258790B2 (ja) | Ｒｈｏキナーゼインヒビター | |
| US5086053A (en) | Derivatives of 1,3,4-thiadiazole, a method of obtaining them and pharmaceutical compositions containing them | |
| JP2007512230A (ja) | プロテインキナーゼ阻害剤として有用な（４−アミノ−１，２，５−オキサジアゾール−４−イル）−ヘテロ芳香族化合物 | |
| MX2007008373A (es) | Derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina y su uso en terapia. | |
| EA024984B1 (ru) | Производные 6-циклоалкил-1,5-дигидропиразоло[3,4-d]пиримидин-4-она и их применение в качестве ингибиторов pde9a | |
| JP2008515992A (ja) | 体細胞変異に起因する疾患の阻止／治療用医薬を製造するための規定化合物の使用 | |
| JP2007500178A (ja) | プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体 | |
| CN108341814B (zh) | Jak激酶抑制剂及其应用 | |
| WO2015038350A2 (en) | Substituted 2, 3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | |
| CA1284325C (en) | Antipsychotic cyclic imide derivatives of 2-(4- butylpiperazin-1-yl) pyridines | |
| KR20040072649A (ko) | 티아디아졸린 유도체 | |
| US9808456B2 (en) | Piperazine thiazole derivatives useful in the treatment of tauopathies such as Alzheimer's disease | |
| HK1192726B (en) | 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | |
| CN1898237B (zh) | 嘧啶-4-基-3,4-硫酮化合物及其治疗用途 | |
| WO2022129914A1 (en) | Alkyne derivatives as inhibitors of c-abl | |
| HK1192848B (en) | Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |